AndroGel and Bupropion Interaction: Safety, Risks, and Clinical Guidance

Why This Combination Comes Up So Often

Men receiving testosterone replacement therapy (TRT) for hypogonadism carry elevated rates of comorbid major depressive disorder. A 2019 analysis of U.S. Commercial claims data (N=41,190 men on TRT) found that 22.8% had a concurrent depression diagnosis, and bupropion ranked among the top three antidepressants prescribed in that cohort [1]. Bupropion also serves as a first-line smoking-cessation aid and a weight-neutral antidepressant option, making it especially attractive in TRT patients concerned about metabolic side effects from SSRIs.

Who Gets Prescribed Both

The typical patient is a man aged 40 to 65 with confirmed low testosterone (total T <300 ng/dL on two morning draws) who also meets DSM-5 criteria for major depressive disorder or is attempting to quit smoking. Because testosterone itself exerts mood-modulating effects through androgen receptor signaling in the limbic system [2], clinicians sometimes start TRT first and reassess depressive symptoms at 8 to 12 weeks before adding an antidepressant.

Why Bupropion Over Other Antidepressants

SSRIs and SNRIs frequently cause sexual dysfunction, a side effect that directly undermines one of the primary goals of TRT. Bupropion's norepinephrine-dopamine reuptake inhibition (NDRI) mechanism carries the lowest rate of treatment-emergent sexual dysfunction among all major antidepressant classes. A 2004 meta-analysis in the Journal of Clinical Psychiatry (N=1,042 across four RCTs) reported sexual dysfunction in 22% of SSRI-treated patients versus 7% with bupropion SR [3].

The CYP2D6 Interaction Mechanism

Bupropion is one of the most potent clinically relevant inhibitors of cytochrome P450 2D6 (CYP2D6). The FDA label for bupropion hydrochloride states that co-administration increased the AUC of desipramine (a CYP2D6 substrate probe) by approximately 5-fold [4]. This raises the question: does CYP2D6 inhibition meaningfully alter testosterone pharmacokinetics?

How Testosterone Is Metabolized

Testosterone undergoes hepatic metabolism primarily through CYP3A4, with secondary contributions from CYP2C9, CYP2C19, and CYP2D6 [5]. The CYP3A4 pathway accounts for roughly 60 to 70% of oxidative metabolism, converting testosterone to 6β-hydroxytestosterone. CYP2D6 contributes an estimated 5 to 15% of total clearance under normal conditions.

Clinical Consequence of CYP2D6 Blockade

Because CYP2D6 handles only a minor fraction of testosterone clearance, potent inhibition by bupropion is unlikely to produce large shifts in steady-state testosterone concentrations. Theoretical modeling suggests a maximal 10 to 20% increase in testosterone AUC when CYP2D6 is fully inhibited, assuming CYP3A4 activity remains intact [5]. This contrasts sharply with strong CYP3A4 inhibitors (ketoconazole, ritonavir), which can double testosterone exposure.

Patients who are CYP2D6 poor metabolizers (PM) at baseline (6 to 10% of Caucasians, 1 to 2% of East Asians) already have reduced CYP2D6 activity [6]. Adding bupropion to a CYP2D6 PM effectively eliminates this pathway entirely, and the incremental testosterone increase may be clinically noticeable. These patients deserve closer monitoring.

When CYP2D6 Status Matters Most

A practical decision framework for this interaction:

• CYP2D6 extensive/normal metabolizer + CYP3A4 uninhibited: low clinical risk; standard monitoring is sufficient.
• CYP2D6 poor metabolizer + CYP3A4 uninhibited: moderate risk; check testosterone levels 4 weeks after starting bupropion.
• Any CYP2D6 phenotype + concurrent CYP3A4 inhibitor (e.g., clarithromycin, itraconazole): highest risk; testosterone levels could rise substantially. Consider dose reduction of AndroGel.

Seizure Threshold: The More Clinically Significant Concern

The seizure risk associated with this combination matters more in day-to-day practice than the CYP2D6 pharmacokinetic interaction. Both agents lower seizure threshold through distinct mechanisms.

Bupropion's Seizure Risk Profile

The FDA label for bupropion reports a dose-dependent seizure incidence: 0.1% (1/1,000) at doses up to 300 mg/day, rising to 0.4% (4/1,000) at doses between 300 and 450 mg/day [4]. Above 450 mg/day, the incidence climbs steeply to approximately 2.1%, which is why the label enforces a 450 mg/day ceiling. The mechanism involves bupropion's inhibition of neuronal norepinephrine and dopamine reuptake, increasing cortical excitability.

Testosterone and Seizure Susceptibility

Testosterone's relationship with seizure threshold is complex. Animal models show that testosterone itself has mild anticonvulsant properties, but its 5α-reduced metabolite dihydrotestosterone (DHT) and aromatized metabolite estradiol exert opposing effects. Estradiol is proconvulsant. A 2005 review in Epilepsy & Behavior documented that supratherapeutic testosterone levels (total T >1,200 ng/dL) are associated with increased seizure frequency in men with pre-existing epilepsy [7]. At physiologic replacement doses, this risk is minimal.

Combined Risk Assessment

The additive seizure risk from combining AndroGel at labeled doses (50 to 100 mg testosterone daily, targeting total T of 300 to 1,000 ng/dL) with bupropion at or below 450 mg/day is modest. No published case series has specifically quantified the combination's seizure incidence. The Endocrine Society's 2018 Clinical Practice Guideline for testosterone therapy does not list bupropion as a contraindicated co-medication [8].

Patients with the following risk factors should receive individual benefit-risk assessment before co-prescribing:

• History of seizure disorder or febrile seizures
• Active eating disorder (bupropion is contraindicated)
• Concurrent use of other seizure-threshold-lowering agents (tramadol, theophylline, systemic corticosteroids)
• Abrupt discontinuation of benzodiazepines or alcohol
• Traumatic brain injury within the prior 12 months

Monitoring Protocol for Co-Administration

A structured monitoring approach reduces risk and catches pharmacokinetic interactions early. The protocol below applies specifically to men starting bupropion while already on stable AndroGel therapy, or vice versa.

Baseline (Before Adding the Second Drug)

Obtain: total testosterone, free testosterone (equilibrium dialysis preferred), sex hormone-binding globulin (SHBG), complete metabolic panel, and a seizure risk screening questionnaire. Document any history of head trauma, alcohol use disorder, or eating disorders.

Week 4

Repeat total and free testosterone. If total T exceeds the upper limit of the reference range (typically >1,000 ng/dL for most labs) and the patient was previously at goal, the CYP2D6-mediated interaction may be contributing. Consider reducing the AndroGel dose by one pump (12.5 mg testosterone for the 1.62% formulation) and rechecking in 4 weeks [9].

Week 12

Repeat total and free testosterone, hematocrit (testosterone raises erythropoietin and can cause polycythemia), and hepatic transaminases. If levels have stabilized within range, extend monitoring to every 6 months, consistent with the Endocrine Society's standard TRT monitoring intervals [8].

Ongoing Seizure Surveillance

No routine EEG is required. Counsel patients to report any episodes of unexplained loss of consciousness, myoclonic jerks, or new-onset tremor. The American Epilepsy Society notes that most drug-induced seizures occur within the first 6 months of exposure to the offending agent [10].

Dose Adjustments: When and How

Routine dose adjustment of either AndroGel or bupropion is not required solely because of co-administration. The interaction is pharmacokinetically minor and pharmacodynamically manageable with monitoring.

Scenarios Requiring AndroGel Dose Reduction

Reduce AndroGel if post-bupropion testosterone levels exceed 1,000 ng/dL on two consecutive draws, or if hematocrit rises above 54% (the Endocrine Society's threshold for intervention) [8]. The typical reduction: AndroGel 1.62% from 4 pumps (81 mg) to 3 pumps (60.75 mg), or AndroGel 1% from two 5-g packets to one 5-g packet.

Scenarios Requiring Bupropion Dose Reduction

Reduce bupropion if the patient develops new tremor, insomnia that persists beyond the expected 1- to 2-week adjustment period, or tachycardia (resting heart rate >100 bpm). These symptoms may reflect bupropion accumulation, particularly in CYP2D6 poor metabolizers where bupropion's own metabolism (to hydroxybupropion via CYP2B6) can be affected by genetic variability [4].

Switching Considerations

If seizure risk is deemed too high for the combination, alternatives include:

• Replacing bupropion with mirtazapine (also weight-neutral, low sexual side-effect burden, does not lower seizure threshold)
• Replacing AndroGel with testosterone cypionate injections (same CYP interaction profile, but allows easier dose titration in 25 mg increments)

Patient Counseling Points

Direct patient education reduces adverse events and improves treatment adherence for both medications.

What to Tell the Patient

"You can take both medications together. There is no absolute restriction. We will check your testosterone blood level at 4 weeks and 12 weeks to make sure the antidepressant is not causing your testosterone to drift higher than intended."

Seizure Precautions

Tell patients: "Bupropion slightly raises the chance of a seizure. Testosterone in high doses can add to that effect. Do not skip doses and then double up. Do not exceed the bupropion dose I have prescribed. Avoid binge drinking, which independently lowers seizure threshold."

Application Site Precautions

AndroGel has a boxed warning regarding secondary exposure through skin-to-skin contact [9]. Bupropion does not alter this risk, but patients should be reminded at every visit: apply AndroGel to clean, dry skin on the shoulders or upper arms, allow it to dry, cover with clothing, and wash hands immediately. Women and children must not contact the application site.

What the Guidelines Say

The Endocrine Society's 2018 guideline on testosterone therapy for men with hypogonadism [8] does not specifically address the bupropion interaction but recommends monitoring hematocrit, PSA, and testosterone levels at 3 to 6 months and then annually. The APA's 2010 Practice Guideline for the Treatment of Patients with Major Depressive Disorder [11] lists bupropion as a first-line agent and notes the seizure risk without contraindicating use with hormonal therapies.

FDA Label Cross-Reference

The AndroGel (testosterone) FDA label [9] warns that testosterone is metabolized by CYP3A4 and lists CYP3A4 inhibitors (but not CYP2D6 inhibitors) as requiring dose monitoring. The bupropion FDA label [4] lists the drug as a "potent CYP2D6 inhibitor" and advises caution with CYP2D6 substrates, though testosterone is not specifically named because its CYP2D6 contribution is minor.

Professional Society Consensus

No major professional society (Endocrine Society, APA, AACE) has issued a formal advisory against this combination. The interaction appears in commercial drug-interaction databases (Lexicomp, Clinical Pharmacology, Micromedex) at a "moderate" severity rating, meaning monitoring is recommended but co-prescribing is not contraindicated [12].

Special Populations

Older Adults (Age >65)

CYP2D6 activity declines modestly with age. Combined with age-related reductions in hepatic blood flow, older men may experience slightly higher testosterone and bupropion levels. The Endocrine Society recommends lower starting TRT doses in men over 65, and the Beers Criteria flag bupropion doses above 300 mg/day in the elderly as a seizure concern [13].

Men with Hepatic Impairment

Both AndroGel and bupropion undergo hepatic metabolism. In moderate hepatic impairment (Child-Pugh B), the bupropion FDA label recommends reducing the dose to 150 mg every other day for bupropion XL [4]. AndroGel dose should be guided by measured testosterone levels rather than empiric reduction, since hepatic impairment may actually decrease testosterone clearance and increase levels.

CYP2D6 Ultra-Rapid Metabolizers

These patients (1 to 2% of Caucasians, up to 29% of certain Ethiopian and Saudi Arabian populations) clear CYP2D6 substrates faster than normal [6]. Bupropion's inhibition of CYP2D6 may paradoxically "normalize" their phenotype. The net effect on testosterone metabolism is negligible, but bupropion itself may be less effective in these patients because they also rapidly metabolize hydroxybupropion.